3 months vs 12 months of romosozumab for postmenopausal osteoporosis

Of possible interest.
The full text of this study is available.
Randomized Controlled Trial Lancet Diabetes Endocrinol
. 2026 Mar;14(3):216-222. doi: 10.1016/S2213-8587(25)00319-5. Epub 2026 Jan 29.
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial
https://pubmed.ncbi.nlm.nih.gov/41621431/